



## IN CELL ART nanocarriers and delivery of therapeutic proteins

Dear Colleagues,

IN CELL ART is proud to be associated with the recent publication in Human Gene Therapy of promising results concerning the treatment of anemia in kidney failure using an innovative way of delivering Erythropoietin (EPO).

This article describes the development of a novel EPO gene delivery system that allows sustained and adjustable expression of EPO over 9 months. This new treatment does not induce inflammation, pathological erythrocytosis, autoimmune anemia and prevents or reverses chronic anemia in an acquired mouse model of renal failure.

This novel way of delivering protein of therapeutic interest using muscle tissue as protein factory renders acquired or inherited systemic proteins deficiencies treatment closer to reality.

To read more:

**Therapy of Anemia in Kidney Failure, Using Plasmid Encoding Erythropoietin**

Richard-Fiardo P, Payen E, Chèvre R, Zuber J, Letrou-Bonneval E, Beuzard Y, Pitard B. *Hum Gene Ther.* (2008) Apr;19(4):331-42.]

Some of your R&D programs would benefit from such a technology ?

Please contact :

Chloe BELLOCQ

[chloe.bellocq@incellart.com](mailto:chloe.bellocq@incellart.com)

and visit us at: **Bio International Convention** in San Diego, June 17-20, 2008

Atlantic Biotherapies Booth N°2601 French Pavillon

**In-Cell-Art**

1 place Alexis Ricordeau – 44093 Nantes Cedex 1 –France

Tel. : +33 (0)2 40 71 67 17 – Fax : +33 (0)2 40 08 75 19 – Email : [info@incellart.com](mailto:info@incellart.com) –

[www.incellart.com](http://www.incellart.com)

SARL au capital de 47 000 euros – RCS NANTES 483 745 899 – TVA FR48483745899 Code APE 7211Z